Oriel Therapeutics Inc. Company Profile

16:39 EST 10th December 2018 | BioPortfolio

Oriel Therapeutics is a leading respiratory drug delivery and development company serving the pharmaceutical, biotechnology, and diagnostic industries in the development and commercialization of innovative pre-metered unit and multi-dose dry powder delivery systems for medicines for asthma and COPD.Our roots are steeped in breakthrough aerosolization technology - which enabled the development of innovative dry powder inhalation delivery devices. Oriel licensed its initial patented technology related to the use of powder specific fluidization signals, developed at the University of North Carolina at Chapel Hill by Oriel's founders. Since its inception the company has developed an expanding portfolio of intellectual property which is now central to its DPI (dry powder inhaler) platforms. In addition, using the same fundamental principles of powder fluidization, the company has developed IP covering the precise movement of poorly flowing powders for potential industrial applications.


Post Office Box 14087
Research Triangle Park
North Carolina
United States of America


Phone: (919) 313-1290

News Articles [692 Associated News Articles listed on BioPortfolio]

Respiratory Generics, PTV News: Apr 19, 2010

Novartis buys Oriel for undisclosed sum

News Headlines, PTV News: Apr 19, 2010

Forthcoming stories - the tests that tell who will benefit from cancer drugs – and who won’t. Elan set to spin off its drug technologies unit; and Novartis buys Oriel to target respiratory generic...

What to consider before selecting a preregistration placement

National recruitment to preregistration placements in England and Wales has been conducted through a computerised recruitment tool called ‘Oriel’ for the second consecutive year.

Insilico to present on human aging biomarker development at the BSRA Scientific Meeting

(InSilico Medicine, Inc.) Insilico Medicine presents on human aging biomarker development at the BSRA Scientific Meeting. The BSRA meeting will take place at Oriel College, Oxford on Sept. 6-8, 2018....

M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin

Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m. The acquisition will add the target company’s CONTEPO™ drug, which...Read More... The post M&As this we...

Roche’s Genentech agrees to buy Jecure Therapeutics

Based in San Diego of California, Jecure Therapeutics is engaged in the discovery of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics president and CE...

HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop d...

Small-Cap Snapshot: Galectin Therapeutics flies after receiving a patent for treating pulmonary fibrosis

Aquinox Pharmaceuticals, Summit Therapeutics and Global Blood Therapeutics are also making news

PubMed Articles [457 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1283 Associated Companies listed on BioPortfolio]

Oriel Therapeutics Inc.

Oriel Therapeutics is a leading respiratory drug delivery and development company serving the pharmaceutical, biotechnology, and diagnostic industries in the development and commercialization of innov...

Sandoz Inc.

Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Oriel Therapeutics Inc." on BioPortfolio

We have published hundreds of Oriel Therapeutics Inc. news stories on BioPortfolio along with dozens of Oriel Therapeutics Inc. Clinical Trials and PubMed Articles about Oriel Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oriel Therapeutics Inc. Companies in our database. You can also find out about relevant Oriel Therapeutics Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Corporate Database Quicklinks

Searches Linking to this Company Record